Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company described as a global leader in minimally invasive treatments for lung disease, with a focus on chronic obstructive pulmonary disease (COPD) and severe emphysema. The LUNG news page on Stock Titan aggregates company press releases and market updates so readers can follow how Pulmonx’s business and capital markets profile evolve over time.
News about Pulmonx often centers on financial results, including quarterly revenue, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA and constant currency revenue growth. Earnings releases also discuss revenue trends between the United States and international markets, reflecting adoption of Zephyr Valve procedures and related technologies in more than 25 countries.
Another recurring theme in Pulmonx news is clinical and commercial progress for the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. The company highlights the Zephyr Valve’s FDA pre-market approval following its designation as a “breakthrough device,” its inclusion in global treatment guidelines, and its role as a standard of care option for certain severe emphysema patients.
Investors and observers will also find corporate governance and leadership updates reported through press releases and corresponding Form 8-K filings, such as the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. Additional news items cover participation in healthcare and growth investor conferences, where management presents Pulmonx’s story to the investment community.
By reviewing the LUNG news feed, readers can track Pulmonx’s reported financial performance, executive transitions, equity inducement grants, and investor outreach activities, all of which provide context for understanding the company’s progress in the COPD and emphysema treatment market.
Pulmonx announced the grant of inducement awards to Mehul Joshi, the new Chief Financial Officer, consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock. The stock option grant has an exercise price of $9.28 per share and will vest over a three-year period, while the restricted stock units will vest over four years. The awards were approved as an inducement to Mr. Joshi's employment under Nasdaq Listing Rule 5635(c)(4).
Pulmonx (Nasdaq: LUNG) reported financial results for Q1 2024, achieving a 30% year-over-year revenue growth, recording $18.9 million in worldwide revenue, with $12.9 million in U.S. revenue. The company realized a gross margin of 75% and treated the first patient in significant clinical trials. Pulmonx appointed new executives to drive growth and expects revenue for 2024 to be in the range of $81 million to $84 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.